Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial

Diabetes, Obesity and Metabolism

Volumn 13, Issue 10, 2011, Pages 947-954

  Lukashevich, Valentina ^a   Schweizer, A ^a   Shao, Q ^a   Groop, P H ^b,c   Kothny, W ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

Author keywords

Adverse drug reactions; Antidiabetic drug; Diabetic nephropathy; DPP IV inhibitor; GLP 1; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE; ALPHA GLUCOSIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; PLACEBO; SULFONYLUREA; VILDAGLIPTIN;

ADULT; AGED; ARTICLE; ASTHENIA; BACKACHE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEART DISEASE; HUMAN; HYPERHIDROSIS; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOGLYCEMIA; INFECTION; INFESTATION; INFLUENZA; INSULIN TREATMENT; KIDNEY DYSFUNCTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PERIPHERAL EDEMA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE; TREMOR; URINARY TRACT INFECTION; VOMITING;

EID: 80052551137     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01467.x     Document Type: Article

References (21)

1. Thomas MC, Weekes AJ, Broadley OJ, Cooper ME, Mathew TH. The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust 2006; 185: 140-144.
2. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis 2007; 50: 865-879.
3. ®XR (metformin hydrochloride extended-release tablets), Princeton, NJ, 2006.
4. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010; 30: 463-484.
5. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab 2010; 12: 485-494.
6. Schweizer A, Dejager S, Foley JE, Kothny W. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag 2011; 7: 49-57.
7. Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 2010; 12: 495-509.
8. Williams-Herman D, Round E, Swern AS et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008; 8: 14.
9. Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011; 13: 523-532.
10. Chan JCN, Scott R, Ferreira JCA et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008; 10: 545-555.
11. He H, Tran P, Yin H et al. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009; 37: 536-544.
12. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132-138.
13. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007; 39: 218-223.
14. Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population 75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab 2011; 13: 55-64.
15. Banerji MA, Purkayastha D, Francis BH. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study. Diabetes Res Clin Pract 2010; 90: 182-190.
16. Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of Action of the DPP-4 Inhibitor Vildagliptin in Man. Diabetes Obes Metab 2011; 13: 775-783.
17. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148-1155.
18. Garber AJ, Foley JE, Banerji MA et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008; 10: 1047-1056.
19. Pratley RE, Rosenstock J, Pi-Sunyer FX et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007; 30: 3017-3022.
20. Williams ME. Management of diabetes in dialysis patients. Curr Diab Rep 2009; 9: 466-472.
21. Ahren B, Schweizer A, Dejager S et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 1236-1243.